Skip to main content
SpringerLink
Log in

Anti-EGFR-Therapie in Kombination mit Radiotherapie für Patienten mit Kopf-Hals-Karzinomen – doch keine therapeutische Revolution

Anti-EGFR therapy in combination with radiotherapy for patients with head and neck carcinoma—not a therapeutic revolution

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28

    Article  CAS  PubMed  Google Scholar 

  2. Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127

    Article  CAS  PubMed  Google Scholar 

  3. Rosenthal DI, Harari PM, Giralt J et al (2014) Impact of p16 status on the results of the phase III cetuximab (cet)/radiotherapy (RT). J Clin Oncol 32:5s

    Article  Google Scholar 

  4. Vermorken JB, Psyrri A, Mesía R et al (2014) Impact oftumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. Ann Oncol 25:801–807

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Mesía R, Henke M, Fortin A et al (2015) Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Lancet Oncol 16:208–202

    Article  PubMed  Google Scholar 

  6. Giralt J, Trigo J, Nuyts S et al (2015) Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous –cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Lancet Oncol 16:221–232

    Article  CAS  PubMed  Google Scholar 

  7. Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578

    Article  CAS  PubMed  Google Scholar 

  8. Pignon JP, le Maitre A, Maillard E et al (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4–14

    Article  PubMed  Google Scholar 

  9. Vermorken JB, Stöhlmacher-Williams J, Davidenko I et al (2013) Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 14:697–710

    Article  CAS  PubMed  Google Scholar 

  10. Ang KK, Zhang Q, Rosenthal DI et al (2014) Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or with out cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 32:2940–2950

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Strahlentherapie und Onkologie, Klinikum der Johann-Wolfgang-Goethe-Universität, Theodor-Stern-Kai 7, 60590, Frankfurt a. M, Deutschland

    Panagiotis Balermpas

Authors
  1. Panagiotis Balermpas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Panagiotis Balermpas.

Ethics declarations

Interessenskonflikt

P. Balermpas gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Additional information

Originalpublikationen

Mesía R, Henke M, Fortin A et al (2015) Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Lancet Oncol 16:208–220

Giralt J, Trigo J, Nuyts S et al (2015) Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Lancet Oncol 16:221–232

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Balermpas, P. Anti-EGFR-Therapie in Kombination mit Radiotherapie für Patienten mit Kopf-Hals-Karzinomen – doch keine therapeutische Revolution. Strahlenther Onkol 191, 619–622 (2015). https://doi.org/10.1007/s00066-015-0845-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-015-0845-z

Search

Navigation